Kanada - anglų - Health Canada

hoffmann-la roche limited - interferon alpha-2a - solution - 36000000unit - interferon alpha-2a 36000000unit - antineoplastic agents

Kanada - anglų - Health Canada

hoffmann-la roche limited - interferon alpha-2a - solution - 9000000unit - interferon alpha-2a 9000000unit - antineoplastic agents

Kanada - anglų - Health Canada

hoffmann-la roche limited - interferon alpha-2a - liquid - 4.5m - interferon alpha-2a 4.5m - antineoplastic agents

Kanada - anglų - Health Canada

hoffmann-la roche limited - interferon alpha-2a - solution - 6m - interferon alpha-2a 6m - antineoplastic agents

Australija - anglų - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: methionine; acetic acid; mannitol; poloxamer; water for injections; benzyl alcohol; sodium hydroxide - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Australija - anglų - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Australija - anglų - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Malta - anglų - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - interferon alfa - solution for injection in a pre-filled syringe - interferon alfa-2a 3 million iu - immunostimulants

Malta - anglų - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - interferon alfa - solution for injection in a pre-filled syringe - interferon alfa-2a 3 million iu - immunostimulants

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 18 miu - powder for injection - 18 miu - active: interferon alfa-2a 18 miu excipient: albumin sodium chloride water for injection